Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors

Future Oncology

Volumn 11, Issue 16, 2015, Pages 2329-2342

  Moschini, Ilaria ^a   Dell'Anna, Cristina ^a   Losardo, Pier Luigi ^a   Bordi, Paola ^a   D'Abbiero, Nunziata ^a   Tiseo, Marcello ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

brain radiotherapy; EGFR; non small cell lung cancer; thoracic radiotherapy; tyrosine kinase inhibitors

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; TEMOZOLOMIDE; PROTEIN KINASE INHIBITOR;

APOPTOSIS; BLOOD BRAIN BARRIER; BRAIN; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CELL CYCLE ARREST; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; GENE EXPRESSION; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INDUCTION CHEMOTHERAPY; LUNG ADENOCARCINOMA; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION PNEUMONIA; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; THORAX; TREATMENT OUTCOME; TUMOR GENE; WHOLE BODY RADIATION; WILD TYPE; ANIMAL; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PRECLINICAL STUDY; PROCEDURES; SECONDARY;

ANIMALS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84939149136     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.156     Document Type: Review

References (56)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. CA Cancer J. Clin. 64(1), 9-29 (2014).
2. Auperin A, Le Pechoux C, Rolland E et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 2181-2189 (2010).
3. Vansteenkiste J, De Ruysscher D, Eberhardt WEE et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl. 6), vi89-vi98 (2013).
4. Besse B, Adjei A, Baas P et al. 2nd ESMO consensus conference on lung cancer: non-small-cell lung cancer frst-line/second and further lines of treatment in advanced disease. Ann. Oncol. 25 (8), 1475-1484 (2014).
5. Mok TS, Wu Y-L, Thongprasert S et al. Geftinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-57 (2009).
6. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as frst-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized Phase 3 trial. Lancet Oncol. 13 (3), 239-246 (2012).
7. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31(27), 3327-3334 (2013).
8. Siegelin MD, Borczuck AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab. Invest. 94, 129-137 (2014).
9. Herbst RS. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 59(Suppl. 2), 21-26 (2004).
10. Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother. Oncol. 72(3), 257-66 (2004).
11. Chinnaiyan P, Huang S, Vallabhaneni G et al Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 65(8), 3328-3335 (2005).
12. Das AK, Chen BP, Story MD et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res. 67(11), 5267-5274 (2007).
13. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
14. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to geftinib therapy. Science 304(5676), 1497-1500 (2004).
15. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to geftinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2(3), e73 (2005).
16. Bokobza SM, Jiang Y, Weber AM, Devery AM, Ryan AJ. Short-course treatment with geftinib enhances curative potential of radiation therapy in a mouse model of human non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 88(4), 947-954 (2014).
17. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J. Clin. Oncol. 31(31), 3987-3996 (2013).
18. de Mello RA, Madureira P, Carvalho LS et al. EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. Pharmacogenomics 14(14), 1765-1777 (2013).
19. Bradley JD, Paulus R, Komaki R et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomized, two-by-two factorial Phase 3 study. Lancet Oncol. 16(2), 187-199 (2015).
20. Stinchcombe TE, Morris DE, Lee CB et al Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and geftinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J. Thorac. Oncol. 3(3), 250-257 (2008).
21. Ball D, Burmeister B, Mitchell P et al. Phase I trial of geftinib in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non small cell lung cancer (CRITICAL). J. Thorac. Oncol. 2(8), S633-S634 (2007).
22. Center B, Petty WJ, Ayala D et al. A Phase I study of geftinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance geftinib for patients with stage III non-small cell lung cancer. J. Thorac. Oncol. 5(1), 69-74 (2010).
23. Rothschild S, Bucher SE, Berrnier J et al. Geftinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a Phase I trial. Int. J. Radiat. Oncol. Biol. Phys. 80(1), 126-132 (2011).
24. Okamoto I, Takahashi T, Okamoto H et al. Single-agent geftinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. Lung Cancer 72(2), 199-204 (2011).
25. Wang T, Yi Xia T, Wang YJ et al. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 81(3), e59-e65(2011).
26. Niho S, Ohe Y, Ishikura S et al. Induction chemotherapy followed by geftinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402). Ann. Oncol. 23(9), 2253-2258 (2012).
27. Choong NW, Mauer AM, Haraf DJ et al. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J. Thorac. Oncol. 3(9), 1003-1011 (2008).
28. Wan J, Cohen V, Agulnik J et al. Unexpected high lung toxicity from radiation pneumonitis in a Phase I/II trial of concurrent erlotinib with limited feld radiation for intermediate prognosis patients with stage III or inoperable stage IIB non-small-cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 75(3) S110 (2009).
29. Ramella S, Alberti AM, Cammiluzzi E et al. Erlotinib and concurrent chemoradiation in pretreated NSCLC patients: radiobilogical and clinical results. BioMed. Res. Int. doi: 10.1155/2013/403869 (2013) (Epub ahead of print).
30. Ready N, Jänne PA, Bogart J et al. Chemoradiotherapy and geftinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis Cancer and Leukemia Group B (CALGB) 30106, a CALGB-Stratifed Phase II Trial. J. Thorac. Oncol. 5(9), 1382-1390 (2010).
31. Lilenbaum R, Samuels M, Wang X et al. A Phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor risk stage III non small cell lung cancer: results CALGB 30605 (Alliance)/RTOG 0972 (NRG). J. Thorac. Oncol. 10(1), 143-147 (2015).
32. Komaki R. Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective Phase II study. Presented at: 15th World Conference on Lung Cancer, International Association for the Study of Lung Cancer. Sydney, Australia, 27-30 October 2013.
33. Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance geftinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: SWOG S0023. J. Clin. Oncol. 26, 2450-2456 (2008).
34. Zhuang H, Yuan Z, Chang JY et al. Radiation pneumonitis in patients with non-small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy. J. Thorac. Oncol. 9(6), 882-885 (2014).
35. Nanda A, Dias-Santagata DC, Stubbs H et al. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer. Clin. Lung Cancer 9(5), 285-287 (2008).
36. Chang CC, Chi KH, Kao SJ et al. Upfront geftinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung Cancer 73 (2), 189-194 (2011).
37. Shin DH, Na II, Kim CH, Park S, Baek H, Yang SH. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J. Thorac. Oncol. 9(2), 195-199 (2014).
38. Hirata H, Nakamura K, Kunitake N et al. Association between EGFR-TKI resistance and effcacy of radiotherapy for brain metastases from EGFR-mutant lung adenocarcinoma. Anticancer Res. 33(4), 1649-5165 (2013).
39. Zhou C, Wu YL, Chen J et al. Erlotinib versus chemotherapy as frst-line treatment for patients with advanced EGFR mutation positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open label, randomized, Phase III study. Lancet Oncol. 12(8), 735-742 (2011).
40. Cai Y, Wang JY, Liu H. Clinical observation of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer patients with chemotherapy failure. Asian Pac. J. Cancer Prev. 14(10), 5699-57703 (2013).
41. Zeng YD, Zhang L, Liao H et al. Geftinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pac. J. Cancer Prev. 13(3), 909-14 (2012).
42. Ma S, Xu Y, Deng Q, Yu X. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and geftinib in a Chinese population. Lung Cancer 65(2), 198-203 (2009).
43. Pesce GA, Klingbiel D, Ribi K et al. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with geftinib or temozolomide. A randomized Phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur. J. Cancer 48(3), 377-84 (2012).
44. Welsh JW, Komaki R, Amini A et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J. Clin. Oncol. 31(7), 895-902 (2013).
45. Zhuang H, Yuan Z, Wang J, Zhao L, Pang Q, Wang P. Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Drug Des. Devel. Ther. 8(7), 1179-1186 (2013).
46. Lee SM, Lewanski CR, Counsell N et al. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. J. Natl Cancer Inst. 106(7), pii: dju151 (2014).
47. Sperduto PW, Wang M, Robins HI et al. A Phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int. J. Radiat. Oncol. Biol. Phys. 85(5), 1312-1318 (2013).
48. Jackman D, Pao W, Riely GJ et al. Clinical defnition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 28(2), 357-360 (2010).
49. Weickhardt AJ, Scheier B, Burke JM et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J. Thorac. Oncol. 7(12), 1807-1814 (2012).
50. Yu HA, Sima CS, Huang J et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J. Thorac. Oncol. 8(3), 346-351 (2013).
51. Inomata M1, Shukuya T, Takahashi T et al. Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer. Anticancer Res. 31(12), 4519-4523 (2011).
52. Shukuya T1, Takahashi T, Naito T et al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer 74 (3), 457-461 (2011).
53. Iyengar P, Kavanagh BD, Wardak Z et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J. Clin. Oncol. 32(34), 3824-3830 (2014).
54. Mak RH, Doran E, Muzikansky A et al. Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist 16(6), 886-895 (2011).
55. Yagishita S, Horinouchi H, Katsui Taniyama T et al. Epidermal growth factor receptor mutation is associated with longer local control after defnitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 91(1), 140-148 (2014).
56. Clinical Trials Database: NCT01822496. https://clinicaltrials.gov